Combating melanoma: The use of photodynamic therapy as a novel, adjuvant therapeutic tool

Cancer Treatment Reviews

Volumn 37, Issue 6, 2011, Pages 465-475

  Davids, L M ^a   Kleemann, B ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Hypericin; Melanin; Melanoma; Melanosomes; Oxidative stress; Photodynamic therapy

Indexed keywords

ANTIOXIDANT; MELANIN; PHOTOSENSITIZING AGENT;

APOPTOSIS; AUTOPHAGY; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; MELANOCYTE; MELANOMA; MELANOSOME; METASTASIS; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LIGHT; MELANOMA; PHOTOCHEMOTHERAPY;

EID: 79960998170     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.11.007     Document Type: Review

References (175)

1. Zbytek B., Carlson J.A., Granese J., et al. Current concepts of metastasis in melanoma. Expert Rev Dermatol 2008, 3:569-585.
2. Carlson J.A., Ross J.S., Slominski A., et al. Molecular diagnostics in melanoma. J Am Acad Dermatol 2005, 52:743-775. [quiz 775-8].
3. Moncrieff M.D., Martin R., O'Brien C.J., et al. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients?. Ann Surg Oncol 2008, 15:3022-3027.
4. Yamamura H., Ugawa S., Ueda T., et al. TRPM8 activation suppresses cellular viability in human melanoma. Am J Physiol Cell Physiol 2008, 295:C296-C301.
5. Chudnovsky Y., Khavari P.A., Adams A.E. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005, 115:813-824.
6. Slominski A., Tobin D.J., Shibahara S., et al. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004, 84:1155-1228.
7. Slominski A., Wortsman J., Carlson A.J., et al. Malignant melanoma. Arch Pathol Lab Med 2001, 125:1295-1306.
8. Thompson J.F., Scolyer R.A., Kefford R.F. Cutaneous melanoma. Lancet 2005, 365:687-701.
9. McMasters K.M., Edwards M.J., Ross M.I., et al. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg 2010, 252:460-465. [discussion 465-6].
10. Wheatley K., Ives N., Hancock B., et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? a meta-analysis of the randomised trials. Cancer Treat Rev 2003, 29:241-252.
11. Mocellin S., Pasquali S., Rossi C.R., et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501.
12. Janku F., Kurzrock R. Adjuvant interferon in high-risk melanoma: end of the era?. J Clin Oncol 2010, 28:e15-e16. [author reply e17-8].
13. Boon T. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 1993, 54:177-180.
14. Vogel T.U., Visan L., Ljutic B., et al. Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother 2010, 33:743-758.
15. Bataille V. Early detection of melanoma improves survival. Practitioner 2009, 253:29-33.
16. Carlson J.A., Ross J.S., Slominski A.J. New techniques in dermatopathology that help to diagnose and prognosticate melanoma. Clin Dermatol 2009, 27:75-102.
17. Gilchrest B.A., Eller M.S., Geller A.C., et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999, 340:1341-1348.
18. Clark W.H., Elder D.E., Guerry D., et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984, 15:1147-1165.
19. Brunet A., Roux D., Lenormand P., et al. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999, 18:664-674.
20. Lin A.W., Barradas M., Stone J.C., et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998, 12:3008-3019.
21. Miller A.J., Mihm M.C. Melanoma. N Engl J Med 2006, 355:51-65.
22. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
23. Buytaert E., Dewaele M., Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 2007, 1776:86-107.
24. Babilas P., Schreml S., Landthaler M., et al. Photodynamic therapy in dermatology: state-of-the-art. Photodermatol Photoimmunol Photomed 2010, 26:118-132.
25. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J Natl Cancer Inst 1998, 90:889-905.
26. Henderson B.W., Dougherty T.J. How does photodynamic therapy work?. Photochem Photobiol 1992, 55:145-157.
27. Juarranz A., Jaen P., Sanz-Rodriguez F., et al. Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 2008, 10:148-154.
28. Ortel B., Shea C.R., Calzavara-Pinton P. Molecular mechanisms of photodynamic therapy. Front Biosci 2009, 14:4157-4172.
29. Gomer C.J., Ferrario A., Luna M., et al. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg Med 2006, 38:516-521.
30. Verma S., Watt G.M., Mai Z., et al. Strategies for enhanced photodynamic therapy effects. Photochem Photobiol 2007, 83:996-1005.
31. Detty M.R., Gibson S.L., Wagner S.J. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem 2004, 47:3897-3915.
32. Stockert J.C., Canete M., Juarranz A., et al. Porphycenes: facts and prospects in photodynamic therapy of cancer. Curr Med Chem 2007, 14:997-1026.
33. Bourre L., Rousset N., Thibaut S., et al. PDT effects of m-THPC and ALA, phototoxicity and apoptosis. Apoptosis 2002, 7:221-230.
34. Thibaut S., Bourre L., Hernot D., et al. Effects of BAPTA-AM, forskolin, DSF and Z.VAD.fmk on PDT-induced apoptosis and m-THPC phototoxicity on B16 cells. Apoptosis 2002, 7:99-106.
35. Szeimies R.M., Karrer S., Radakovic-Fijan S., et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002, 47:258-262.
36. Szeimies R.M. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol Clin 2007, 25:89-94.
37. Szeimies R.M., Morton C.A., Sidoroff A., et al. Photodynamic therapy for non-melanoma skin cancer. Acta Derm Venereol 2005, 85:483-490.
38. Chen B., Xu Y., Agostinis P., et al. Synergistic effect of photodynamic therapy with hypericin in combination with hyperthermia on loss of clonogenicity of RIF-1 cells. Int J Oncol 2001, 18:1279-1285.
39. Alecu M., Ursaciuc C., Halalau F., et al. Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin. Anticancer Res 1998, 18:4651-4654.
40. Bublik M., Head C., Benharash P., et al. Hypericin and pulsed laser therapy of squamous cell cancer in vitro. Photomed Laser Surg 2006, 24:341-347.
41. Chung P.S., Rhee C.K., Kim K.H., et al. Intratumoral hypericin and KTP laser therapy for transplanted squamous cell carcinoma. Laryngoscope 2000, 110:1312-1316.
42. Chung P.S., Saxton R.E., Paiva M.B., et al. Hypericin uptake in rabbits and nude mice transplanted with human squamous cell carcinomas: study of a new sensitizer for laser phototherapy. Laryngoscope 1994, 104:1471-1476.
43. Liu C.D., Kwan D., Saxton R.E., et al. Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. J Surg Res 2000, 93:137-143.
44. D'Hallewin M.A., Kamuhabwa A.R., Roskams T., et al. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int 2002, 89:760-763.
45. D'Hallewin M.A., De Witte P.A., Waelkens E., et al. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J Urol 2000, 164:349-351.
46. Kubin A., Loew H.G., Burner U., et al. How to make hypericin water-soluble. Pharmazie 2008, 63:263-269.
47. Sim H.G., Lau W.K., Olivo M., et al. Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma?. BJU Int 2005, 95:1215-1218.
48. Kubin A., Meissner P., Wierrani F., et al. Fluorescence diagnosis of bladder cancer with new water soluble hypericin bound to polyvinylpyrrolidone: PVP-hypericin. Photochem Photobiol 2008, 84:1560-1563.
49. Bhuvaneswari R., Gan Y.Y., Yee K.K., et al. Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma. Int J Mol Med 2007, 20:421-428.
50. Olivo M., Du H.Y., Bay B.H. Hypericin lights up the way for the potential treatment of nasopharyngeal cancer by photodynamic therapy. Curr Clin Pharmacol 2006, 1:217-222.
51. Kacerovska D., Pizinger K., Majer F., et al. Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract - a pilot study. Photochem Photobiol 2008, 84:779-785.
52. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
53. Cory A.H., Owen T.C., Barltrop J.A., et al. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991, 3:207-212.
54. VanderWerf Q.M., Saxton R.E., Chang A., et al. Hypericin: a new laser phototargeting agent for human cancer cells. Laryngoscope 1996, 106:479-483.
55. Hadjur C., Richard M.J., Parat M.O., et al. Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells. Photochem Photobiol 1996, 64:375-381.
56. Davids L.M., Kleemann B., Kacerovska D., et al. Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B 2008, 91:67-76.
57. Davids L.M., Kleemann B., Cooper S., et al. Melanomas display increased cytoprotection to hypericin-mediated cytotoxicity through the induction of autophagy. Cell Biol Int 2009, 33:1065-1072.
58. Wellbrock C., Weisser C., Geissinger E., et al. Activation of p59(fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J Biol Chem 2002, 277:6443-6454.
59. Cohen C., Zavala-Pompa A., Sequeira J.H., et al. Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002, 8:3728-3733.
60. Tsao H., Goel V., Wu H., et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004, 122:337-341.
61. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
62. Gray-Schopfer V.C., da Rocha Dias S., Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005, 24:165-183.
63. Tong Z., Singh G., Rainbow A.J. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy. Cancer Res 2002, 62:5528-5535.
64. Mercurio F., Manning A.M. NF-kappaB as a primary regulator of the stress response. Oncogene 1999, 18:6163-6171.
65. Ryter S.W., Gomer C.J. Nuclear factor kappa B binding activity in mouse L1210 cells following photofrin II-mediated photosensitization. Photochem Photobiol 1993, 58:753-756.
66. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
67. Oleinick N.L., Morris R.L., Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 2002, 1:1-21.
68. Agostinis P., Buytaert E., Breyssens H., et al. Regulatory pathways in photodynamic therapy induced apoptosis. Photochem Photobiol Sci 2004, 3:721-729.
69. Buytaert E., Callewaert G., Vandenheede J.R., et al. Deficiency in apoptotic effectors bax and bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy 2006, 2:238-240.
70. Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell 1994, 78:539-542.
71. Micheau O., Solary E., Hammann A., et al. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 1997, 89:783-789.
72. Ali S.M., Chee S.K., Yuen G.Y., et al. Hypericin induced death receptor-mediated apoptosis in photoactivated tumor cells. Int J Mol Med 2002, 9:601-616.
73. Reiners J.J., Agostinis P., Berg K., et al. Assessing autophagy in the context of photodynamic therapy. Autophagy 2010, 6:7-18.
74. Dewaele M., Maes H., Agostinis P. ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy 2010, 6:838-854.
75. Buytaert E., Callewaert G., Hendrickx N., et al. Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. FASEB J 2006, 20:756-758.
76. Ritz R., Roser F., Radomski N., et al. Subcellular colocalization of hypericin with respect to endoplasmic reticulum and Golgi apparatus in glioblastoma cells. Anticancer Res 2008, 28:2033-2038.
77. Davids L.M., Kleemann B., Kacerovska D., et al. Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B 2008, 91:67-76.
78. Galanou M.C., Theodossiou T.A., Tsiourvas D., et al. Interactive transport, subcellular relocation and enhanced phototoxicity of hypericin encapsulated in guanidinylated liposomes via molecular recognition. Photochem Photobiol 2008, 84:1073-1083.
79. Ali S.M., Olivo M. Bio-distribution and subcellular localization of hypericin and its role in PDT induced apoptosis in cancer cells. Int J Oncol 2002, 21:531-540.
80. Ali S.M., Chee S.K., Yuen G.Y., et al. Hypericin induced death receptor-mediated apoptosis in photoactivated tumor cells. Int J Mol Med 2002, 9:601-616.
81. English D.S., Doyle R.T., Petrich J.W., et al. Subcellular distributions and excited-state processes of hypericin in neurons. Photochem Photobiol 1999, 69:301-305.
82. Crnolatac I., Huygens A., Agostinis P., et al. In vitro accumulation and permeation of hypericin and lipophilic analogues in 2-D and 3-D cellular systems. Int J Oncol 2007, 30:319-324.
83. Theodossiou T.A., Hothersall J.S., De Witte P.A., et al. The multifaceted photocytotoxic profile of hypericin. Mol Pharm 2009.
84. Ho Y.F., Wu M.H., Cheng B.H., et al. Lipid-mediated preferential localization of hypericin in lipid membranes. Biochim Biophys Acta 2009, 1788:1287-1295.
85. Mojzisova H., Bonneau S., Brault D. Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells. Eur Biophys J 2007, 36:943-953.
86. Buytaert E., Matroule J.Y., Durinck S., et al. Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells. Oncogene 2008, 27:1916-1929.
87. Verfaillie T., Salazar M., Velasco G., et al. Linking ER stress to autophagy: potential implications for cancer therapy. Int J Cell Biol 2010, 2010:1-19.
88. Thomas C., MacGill R.S., Miller G.C., et al. Photoactivation of hypericin generates singlet oxygen in mitochondria and inhibits succinoxidase. Photochem Photobiol 1992, 55:47-53.
89. Miccoli L., Beurdeley-Thomas A., De Pinieux G., et al. Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. Cancer Res 1998, 58:5777-5786.
90. Theodossiou T.A., Papakyriakou A., Hothersall J.S. Molecular modeling and experimental evidence for hypericin as a substrate for mitochondrial complex III; mitochondrial photodamage as demonstrated using specific inhibitors. Free Radic Biol Med 2008, 45:1581-1590.
91. Utsumi T., Okuma M., Kanno T., et al. Effect of the antiretroviral agent hypericin on rat liver mitochondria. Biochem Pharmacol 1995, 50:655-662.
92. Buytaert E., Callewaert G., Vandenheede J.R., et al. Deficiency in apoptotic effectors bax and bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy 2006, 2:238-240.
93. Young A.R., Narita M., Ferreira M., et al. Autophagy mediates the mitotic senescence transition. Genes Dev 2009, 23:798-803.
94. Lu Z., Luo R.Z., Lu Y., et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 2008, 118:3917-3929.
95. Gewirtz D.A. Autophagy, senescence and tumor dormancy in cancer therapy. Autophagy 2009, 5:1232-1234.
96. Nystrom T. Role of oxidative carbonylation in protein quality control and senescence. EMBO J 2005, 24:1311-1317.
97. Pattingre S., Tassa A., Qu X., et al. Bcl-2 antiapoptotic proteins inhibit beclin 1-dependent autophagy. Cell 2005, 122:927-939.
98. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
99. Szatrowski T.P., Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991, 51:794-798.
100. Toyokuni S., Okamoto K., Yodoi J., et al. Persistent oxidative stress in cancer. FEBS Lett 1995, 358:1-3.
101. Sander C.S., Chang H., Hamm F., et al. Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int J Dermatol 2004, 43:326-335.
102. Lincoln D.T., Ali Emadi E.M., Tonissen K.F., et al. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 2003, 23:2425-2433.
103. Cen D., Gonzalez R.I., Buckmeier J.A., et al. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther 2002, 1:197-204.
104. Cen D., Brayton D., Shahandeh B., et al. Disulfiram facilitates intracellular cu uptake and induces apoptosis in human melanoma cells. J Med Chem 2004, 47:6914-6920.
105. Huang P., Feng L., Oldham E.A., et al. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000, 407:390-395.
106. Dobos J., Timar J., Bocsi J., et al. In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. Int J Cancer 2004, 112:771-776.
107. Russo G.L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 2007, 74:533-544.
108. Tyagi A.K., Singh R.P., Agarwal C., et al. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002, 8:3512-3519.
109. De Larco J.E., Park C.A., Dronava H., et al. Paradoxical roles for antioxidants in tumor prevention and eradication. Cancer Biol Ther 2010, 9:362-370.
110. Farmer P.J., Gidanian S., Shahandeh B., et al. Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res 2003, 16:273-279.
111. Chen K.G., Valencia J.C., Lai B., et al. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci USA 2006, 103:9903-9907.
112. Chen K.G., Leapman R.D., Zhang G., et al. Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst 2009, 101:1259-1271.
113. Raposo G., Marks M.S. The dark side of lysosome-related organelles: specialization of the endocytic pathway for melanosome biogenesis. Traffic 2002, 3:237-248.
114. Hearing V.J. Biogenesis of pigment granules: a sensitive way to regulate melanocyte function. J Dermatol Sci 2005, 37:3-14.
115. Solano F., Martinez-Esparza M., Jimenez-Cervantes C., et al. New insights on the structure of the mouse silver locus and on the function of the silver protein. Pigment Cell Res 2000, 13(Suppl. 8):118-124.
116. Kwon B.S., Chintamaneni C., Kozak C.A., et al. A melanocyte-specific gene, pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. Proc Natl Acad Sci USA 1991, 88:9228-9232.
117. Theos A.C., Truschel S.T., Raposo G., et al. The silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res 2005, 18:322-336.
118. Orlow S.J. Melanosomes are specialized members of the lysosomal lineage of organelles. J Invest Dermatol 1995, 105:3-7.
119. Raposo G., Tenza D., Murphy D.M., et al. Distinct protein sorting and localization to premelanosomes, melanosomes, and lysosomes in pigmented melanocytic cells. J Cell Biol 2001, 152:809-824.
120. Valencia J.C., Hoashi T., Pawelek J.M., et al. Pmel17: controversial indeed but critical to melanocyte function. Pigment Cell Res 2006, 19:250-252. [author reply 253-7].
121. Meyskens F.L., Farmer P., Fruehauf J.P. Redox regulation in human melanocytes and melanoma. Pigment Cell Res 2001, 14:148-154.
122. Ouedraogo M., De Maesschalck E., Soentjens-Werts V., et al. In vitro cytotoxicity study of oxaziridines generated after chlordiazepoxide, demoxepam, and desmethylchlordiazepoxide UV irradiation. Drug Chem Toxicol 2009, 32:417-423.
123. Camerin M., Rello-Varona S., Villanueva A., et al. Metallo-naphthalocyanines as photothermal sensitisers for experimental tumours: in vitro and in vivo studies. Lasers Surg Med 2009, 41:665-673.
124. Krestyn E., Kolarova H., Bajgar R., et al. Photodynamic properties of ZnTPPS(4), ClAlPcS(2) and ALA in human melanoma G361 cells. Toxicol In Vitro 2010, 24:286-291.
125. Zhao B., Yin J.J., Bilski P.J., et al. Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol Appl Pharmacol 2009, 241:163-172.
126. Mamoon A.M., Gamal-Eldeen A.M., Ruppel M.E., et al. In vitro efficiency and mechanistic role of indocyanine green as photodynamic therapy agent for human melanoma. Photodiagnosis Photodyn Ther 2009, 6:105-116.
127. Davids L.M., Kleemann B., Cooper S., et al. Melanomas display increased cytoprotection to hypericin-mediated cytotoxicity through the induction of autophagy. Cell Biol Int 2009, 33:1065-1072.
128. Kolarova H., Tomankova K., Bajgar R., et al. Photodynamic and sonodynamic treatment by phthalocyanine on cancer cell lines. Ultrasound Med Biol 2009, 35:1397-1404.
129. Tsai T., Ji H.T., Chiang P.C., et al. ALA-PDT results in phenotypic changes and decreased cellular invasion in surviving cancer cells. Lasers Surg Med 2009, 41:305-315.
130. Chen Y., Zheng W., Li Y., et al. Apoptosis induced by methylene-blue-mediated photodynamic therapy in melanomas and the involvement of mitochondrial dysfunction revealed by proteomics. Cancer Sci 2008, 99:2019-2027.
131. Hao E., Friso E., Miotto G., et al. Synthesis and biological investigations of tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC). Org Biomol Chem 2008, 6:3732-3740.
132. Chang C.J., Yu J.S., Wei F.C. In vitro and in vivo photosensitizing applications of photofrin in malignant melanoma cells. Chang Gung Med J 2008, 31:260-267.
133. Kolarova H., Nevrelova P., Tomankova K., et al. Production of reactive oxygen species after photodynamic therapy by porphyrin sensitizers. Gen Physiol Biophys 2008, 27:101-105.
134. Skidan I., Dholakia P., Torchilin V. Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5, 10, 15, 20-tetraphenylporphin-loaded PEG-PE micelles. J Drug Target 2008, 16:486-493.
135. Schmitt F., Govindaswamy P., Suss-Fink G., et al. Ruthenium porphyrin compounds for photodynamic therapy of cancer. J Med Chem 2008, 51:1811-1816.
136. Ma L.W., Nielsen K.P., Iani V., et al. A new method for photodynamic therapy of melanotic melanoma - effects of depigmentation with violet light photodynamic therapy. J Environ Pathol Toxicol Oncol 2007, 26:165-172.
137. Janczyk A., Wolnicka-Glubisz A., Urbanska K., et al. Photodynamic activity of platinum(IV) chloride surface-modified TiO2 irradiated with visible light. Free Radic Biol Med 2008, 44:1120-1130.
138. Tomankova K., Kolarova H., Vujtek M., et al. Photodynamic effect on melanoma cells investigated by atomic force microscopy. Gen Physiol Biophys 2007, 26:200-206.
139. Frank J., Lornejad-Schafer M.R., Schoffl H., et al. Inhibition of heme oxygenase-1 increases responsiveness of melanoma cells to ALA-based photodynamic therapy. Int J Oncol 2007, 31:1539-1545.
140. Fabris C., Vicente M.G., Hao E., et al. Tumour-localizing and -photosensitising properties of meso-tetra(4-nido-carboranylphenyl)porphyrin (H2TCP). J Photochem Photobiol B 2007, 89:131-138.
141. Rijcken C.J., Hofman J.W., van Zeeland F., et al. Photosensitiser-loaded biodegradable polymeric micelles: preparation, characterisation and in vitro PDT efficacy. J Control Release 2007, 124:144-153.
142. Kolarova H., Nevrelova P., Bajgar R., et al. In vitro photodynamic therapy on melanoma cell lines with phthalocyanine. Toxicol In Vitro 2007, 21:249-253.
143. Dabrowski J.M., Pereira M.M., Arnaut L.G., et al. Synthesis, photophysical studies and anticancer activity of a new halogenated water-soluble porphyrin. Photochem Photobiol 2007, 83:897-903.
144. Kolarova H., Bajgar R., Tomankova K., et al. Comparison of sensitizers by detecting reactive oxygen species after photodynamic reaction in vitro. Toxicol In Vitro 2007, 21:1287-1291.
145. Ferrario A., Rucker N., Wong S., et al. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res 2007, 67:4989-4995.
146. Hiruma H., Katakura T., Takenami T., et al. Vesicle disruption, plasma membrane bleb formation, and acute cell death caused by illumination with blue light in acridine orange-loaded malignant melanoma cells. J Photochem Photobiol B 2007, 86:1-8.
147. Nowak-Sliwinska P., Karocki A., Elas M., et al. Verteporfin, photofrin II, and merocyanine 540 as PDT photosensitizers against melanoma cells. Biochem Biophys Res Commun 2006, 349:549-555.
148. Friso E., Roncucci G., Dei D., et al. A novel 10B-enriched carboranyl-containing phthalocyanine as a radio- and photo-sensitising agent for boron neutron capture therapy and photodynamic therapy of tumours: in vitro and in vivo studies. Photochem Photobiol Sci 2006, 5:39-50.
149. Saczko J., Kulbacka J., Chwilkowska A., et al. The influence of photodynamic therapy on apoptosis in human melanoma cell line. Folia Histochem Cytobiol 2005, 43:129-132.
150. Kolarova H., Macecek J., Nevrelova P., et al. Photodynamic therapy with zinc-tetra(p-sulfophenyl)porphyrin bound to cyclodextrin induces single strand breaks of cellular DNA in G361 melanoma cells. Toxicol In Vitro 2005, 19:971-974.
151. Camerin M., Rello S., Villanueva A., et al. Photothermal sensitisation as a novel therapeutic approach for tumours: studies at the cellular and animal level. Eur J Cancer 2005, 41:1203-1212.
152. Macecek J., Kolarova H., Psotova J., et al. Assessment of cellular damage by comet assay after photodynamic therapy in vitro. Acta Med (Hradec Kralove) 2004, 47:327-329.
153. Posen Y., Kalchenko V., Seger R., et al. Manipulation of redox signaling in mammalian cells enabled by controlled photogeneration of reactive oxygen species. J Cell Sci 2005, 118:1957-1969.
154. Camerin M., Rodgers M.A., Kenney M.E., et al. Photothermal sensitisation: evidence for the lack of oxygen effect on the photosensitising activity. Photochem Photobiol Sci 2005, 4:251-253.
155. Schastak S., Jean B., Handzel R., et al. Improved pharmacokinetics, biodistribution and necrosis in vivo using a new near infra-red photosensitizer: tetrahydroporphyrin tetratosylat. J Photochem Photobiol B 2005, 78:203-213.
156. Vena F.C., Turchiello R.F., Laville I., et al. 5-Aminolevulinic acid ester-induced protoporphyrin IX in a murine melanoma cell line. Lasers Med Sci 2004, 19:119-126.
157. Ropp S., Guy J., Berl V., et al. Synthesis and photocytotoxic activity of new alpha-methylene-gamma-butyrolactone-psoralen heterodimers. Bioorg Med Chem 2004, 12:3619-3625.
158. Ickowicz Schwartz D., Gozlan Y., Greenbaum L., et al. Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma. Br J Cancer 2004, 90:1833-1841.
159. Barge J., Decreau R., Julliard M., et al. Killing efficacy of a new silicon phthalocyanine in human melanoma cells treated with photodynamic therapy by early activation of mitochondrion-mediated apoptosis. Exp Dermatol 2004, 13:33-44.
160. Szurko A., Kramer-Marek G., Widel M., et al. Photodynamic effects of two water soluble porphyrins evaluated on human malignant melanoma cells in vitro. Acta Biochim Pol 2003, 50:1165-1174.
161. Kolarova H., Mosinger J., Lenobel R., et al. In vitro toxicity testing of supramolecular sensitizers for photodynamic therapy. Toxicol In Vitro 2003, 17:775-778.
162. Nagata S., Obana A., Gohto Y., et al. Necrotic and apoptotic cell death of human malignant melanoma cells following photodynamic therapy using an amphiphilic photosensitizer, ATX-S10(na). Lasers Surg Med 2003, 33:64-70.
163. Haddad R., Kaplan O., Greenberg R., et al. Photodynamic therapy of murine colon cancer and melanoma using systemic aminolevulinic acid as a photosensitizer. Int J Surg Investig 2000, 2:171-178.
164. Urbanska K., Romanowska-Dixon B., Matuszak Z., et al. Indocyanine green as a prospective sensitizer for photodynamic therapy of melanomas. Acta Biochim Pol 2002, 49:387-391.
165. Bourre L., Rousset N., Thibaut S., et al. PDT effects of m-THPC and ALA, phototoxicity and apoptosis. Apoptosis 2002, 7:221-230.
166. Lang K., Bolsen K., Stahl W., et al. The 5-aminolevulinic acid-induced porphyrin biosynthesis in benign and malignant cells of the skin. J Photochem Photobiol B 2001, 65:29-34.
167. Drzewiecka A., Urbanska K., Matuszak Z., et al. Tritolylporphyrin dimer as a new potent hydrophobic sensitizer for photodynamic therapy of melanoma. Acta Biochim Pol 2001, 48:277-282.
168. Rice L., Wainwright M., Phoemix D.A. Phenothiazine photosensitizers. III. Activity of methylene blue derivatives against pigmented melanoma cell lines. J Chemother 2000, 12:94-104.
169. Busetti A., Soncin M., Reddi E., et al. Photothermal sensitization of amelanotic melanoma cells by ni(II)-octabutoxy-naphthalocyanine. J Photochem Photobiol B 1999, 53:103-109.
170. Soncin M., Busetti A., Fusi F., et al. Irradiation of amelanotic melanoma cells with 532 nm high peak power pulsed laser radiation in the presence of the photothermal sensitizer cu(II)-hematoporphyrin: a new approach to cell photoinactivation. Photochem Photobiol 1999, 69:708-712.
171. Decreau R., Richard M.J., Verrando P., et al. Photodynamic activities of silicon phthalocyanines against achromic M6 melanoma cells and healthy human melanocytes and keratinocytes. J Photochem Photobiol B 1999, 48:48-56.
172. Klotz L.O., Fritsch C., Briviba K., et al. Activation of JNK and p38 but not ERK MAP kinases in human skin cells by 5-aminolevulinate-photodynamic therapy. Cancer Res 1998, 58:4297-4300.
173. Blom D.J., Schuitmaker H.J., de Waard-Siebinga I., et al. Decreased expression of HLA class I on ocular melanoma cells following in vitro photodynamic therapy. Cancer Lett 1997, 112:239-243.
174. Rosenbach-Belkin V., Chen L., Fiedor L., et al. Serine conjugates of chlorophyll and bacteriochlorophyll: photocytotoxicity in vitro and tissue distribution in mice bearing melanoma tumors. Photochem Photobiol 1996, 64:174-181.
175. Dellian M., Richert C., Gamarra F., et al. Photodynamic eradication of amelanotic melanoma of the hamster with fast acting photosensitizers. Int J Cancer 1996, 65:246-248.